Cargando…

Inhibition of KIT-Glycosylation by 2-Deoxyglucose Abrogates KIT-Signaling and Combination with ABT-263 Synergistically Induces Apoptosis in Gastrointestinal Stromal Tumor

Positron emission tomography (PET) with (18)F-fluorodeoxyglucose (FDG) is frequently used for visualizing gastrointestinal stromal tumors (GIST), which are highly glucose-avid tumors. Dramatic metabolic responses following imatinib treatment indicate a high, KIT-dependent glucose turnover which has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mühlenberg, Thomas, Grunewald, Susanne, Treckmann, Jürgen, Podleska, Lars, Schuler, Martin, Fletcher, Jonathan A., Bauer, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364009/ https://www.ncbi.nlm.nih.gov/pubmed/25781619 http://dx.doi.org/10.1371/journal.pone.0120531

Ejemplares similares

Efficient Elimination of Cancer Cells by Deoxyglucose-ABT-263/737 Combination Therapy
por: Yamaguchi, Ryuji, et al.
Publicado: (2011)

ABT-263 Enhances Sensitivity to Metformin and 2-Deoxyglucose in Pediatric Glioma by Promoting Apoptotic Cell Death
por: Levesley, Jane, et al.
Publicado: (2013)

Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs)
por: Heinrich, Michael C., et al.
Publicado: (2019)

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
por: Edris, Badreddin, et al.
Publicado: (2013)

Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells
por: Yu, Rui, et al.
Publicado: (2021)

p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors
por: Henze, Joern, et al.
Publicado: (2012)

Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2019)

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors
por: Gao, Jing, et al.
Publicado: (2016)

Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor
por: Katz, Steven C, et al.
Publicado: (2013)

Coordinated targeting of CK2 and KIT in gastrointestinal stromal tumours
por: Huang, Mengyuan, et al.
Publicado: (2019)

Single Agent and Synergistic Activity of Maritoclax with ABT-263 in Nasopharyngeal Carcinoma (NPC) Cell Lines
por: Xiang, Benedict Lian Shi, et al.
Publicado: (2020)

Frequent KIT Mutations in Human Gastrointestinal Stromal Tumors
por: Xu, Zhi, et al.
Publicado: (2014)

C-Kit-Negative Gastrointestinal Stromal Tumor in the Stomach
por: Seo, Ho Seok, et al.
Publicado: (2015)

Combining Paclitaxel with ABT-263 Has a Synergistic Effect on Paclitaxel Resistant Prostate Cancer Cells
por: Wang, Chihuei, et al.
Publicado: (2015)

Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib
por: Falkenhorst, Johanna, et al.
Publicado: (2016)

ABT-263 Reduces Hypertrophic Scars by Targeting Apoptosis of Myofibroblasts
por: Yang, Xiaolan, et al.
Publicado: (2021)

Gastrointestinal stromal tumor with KIT mutation in neurofibromatosis type 1
por: Namgung, Hwan
Publicado: (2011)

Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors
por: Caenepeel, Sean, et al.
Publicado: (2010)

Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis
por: Ke, Hengning, et al.
Publicado: (2016)

KCTD12 is negatively regulated by Kit in gastrointestinal stromal tumors
por: Suehara, Yoshiyuki, et al.
Publicado: (2018)

Morphological Correlates of KIT and PDGFRA Genotypes in Gastrointestinal Stromal Tumour
por: Priya, Valli, et al.
Publicado: (2020)

Spectrum of the KIT Gene Mutations in Gastrointestinal Stromal Tumors in Arab Patients
por: Faiyaz-Ul-Haque, Muhammad, et al.
Publicado: (2018)

KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors
por: Palomba, Grazia, et al.
Publicado: (2020)

Discovery of novel potential KIT inhibitors for the treatment of gastrointestinal stromal tumor
por: Jiang, Lili, et al.
Publicado: (2021)

Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors
por: Obata, Y, et al.
Publicado: (2017)

Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
por: Bauer, Sebastian, et al.
Publicado: (2021)

Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells
por: Airiau, Kelly, et al.
Publicado: (2015)

Gastrointestinal Stromal Tumours treated before and after the advent of c-kit immunostaining
por: Sorelli, Paolo G, et al.
Publicado: (2011)

A Case of KIT-Negative Extra-Gastrointestinal Stromal Tumor of the Lesser Omentum
por: Ogawa, Hisataka, et al.
Publicado: (2012)

Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor
por: Zhang, Dengyang, et al.
Publicado: (2022)

Mutational Analysis of c-KIT and PDGFRA in Canine Gastrointestinal Stromal Tumors (GISTs)
por: Morini, Maria, et al.
Publicado: (2022)

Survivin is a novel transcription regulator of KIT and is downregulated by miRNA‐494 in gastrointestinal stromal tumors
por: Yun, SeongJu, et al.
Publicado: (2018)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia
por: Murray, Heather C., et al.
Publicado: (2023)

Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines
por: Lian, Benedict Shi Xiang, et al.
Publicado: (2018)

ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer
por: Chen, Qiongrong, et al.
Publicado: (2015)

KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib
por: Wang, Guihua, et al.
Publicado: (2019)

The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting
por: Maleddu, Alessandra, et al.
Publicado: (2011)

Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors
por: Merkelbach-Bruse, Sabine, et al.
Publicado: (2010)

Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis
por: Zong, Liang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s5fserp97r5ojsvatm2a1nfurj